[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
[ Fri, Aug 23rd 2024 ]: WOPRAI
Keay Nakae Maintained (SONN) at Strong Buy and Held Target at $240 on, Aug 23rd, 2024
- 🞛 This publication is a summary or evaluation of another publication
- 🞛 This publication contains potentially derogatory content such as foul language or violent themes
Keay Nakae of Chardan Capital, Maintained "Sonnet BioTherapeutics Holdings, Inc." (SONN) at Strong Buy and Held Target at $240 on, Aug 23rd, 2024.
Keay has made no other calls on SONN in the last 4 months.
There is 1 other peer that has a rating on SONN. Out of the 1 peers that are also analyzing SONN, 0 agree with Keay's Rating of Hold.
This is the rating of the analyst that currently disagrees with Keay
- Tim Moore of "EF Hutton" Maintained at Strong Buy with Decreased Target to $56 on, Thursday, May 16th, 2024